Med Spa & Pharmacy Compounded Medication Due Diligence

Medication sourcing in aesthetic and wellness medicine increasingly sits at the intersection of medical spas, 503A compounding pharmacies, and 503B outsourcing facilities. Each plays a distinct but interconnected role in the supply chain.

There is shared responsibility in ensuring that compounded medications are sourced, handled, and administered in a way that is compliant, traceable, and aligned with patient safety expectations.

While compounding plays an essential role when commercially available products do not meet clinical needs, it also introduces additional layers of complexity. As a result, structured supplier due diligence is no longer optional. It is a core component of clinical risk management and regulatory alignment.

The Compounding Ecosystem: Distinct Roles, Shared Risk

Compounded products may be considered when commercially available products do not meet a patient’s clinical needs, including differences in dosage form, strength, formulation, or other requirements. Compounding can often fill the gap during drug shortages as well.

503B outsourcing facilities operate as the infrastructure layer of the compounding ecosystem. They are permitted to produce sterile compounded medications in bulk and distribute them to healthcare facilities for office use, without requiring patient-specific prescriptions.

503A compounding pharmacies, by contrast, operate within a prescription-based model, compounding medications for specific patients pursuant to a valid prescription under the oversight of state boards of pharmacy.

Medical spas and clinical organizations may interact with both:

• Sourcing office-use medications from 503Bs

• Relying on 503As for patient-specific prescribing and fulfillment

At the same time, some 503A pharmacies may obtain certain compounded sterile preparations from 503B outsourcing facilities as part of their operational model, subject to applicable federal and state requirements.

This creates a multi-layered ecosystem where medication access is no longer linear, but shared across clinical, compounding, and distribution pathways.

As a result, both med spas and pharmacies are increasingly responsible for conducting structured supplier due diligence. The goal is not only to ensure product quality and regulatory compliance, but also to maintain continuity of care, mitigate risk, and adapt to an evolving compounding landscape.

For organizations looking to formalize this process, we’ve translated these principles into a structured audit tool that standardizes supplier evaluation across 503A and 503B relationships.

Download the audit tool here: https://mailchi.mp/1dcfefe2ce3b/0a5dxebv0a

Due Diligence as a Structured Process

Guidance from organizations such as the American Society of Health-System Pharmacists and the Institute for Safe Medication Practices consistently emphasizes the importance of evaluating compounding partners across multiple dimensions.

At a high level, effective due diligence should address:

• Regulatory alignment
  Verification of licensure, registration status, and compliance with applicable federal and state requirements

• Quality systems and compounding practices
  Alignment with applicable standards (e.g., cGMP for 503Bs, USP <795>/<797>/<800> for 503As), including environmental controls, testing, and process validation

• Sourcing integrity and product legitimacy
  Confidence that ingredients and compounded products meet applicable quality standards and regulatory requirements

• Documentation and traceability
  The ability to track products from sourcing through administration, including batch-level and patient-level documentation

• Operational reliability
  Consistency in fulfillment, communication, and support of clinical workflows

Importantly, these are not one-time checks. Due diligence should be documented, repeatable, and subject to ongoing review.

Related: Med Spa Compliance: Key Trends, Risks & Guidance for Owners

503B vs. 503A: Different Models, Different Evaluation Priorities

While there is overlap in evaluation criteria, the focus of due diligence differs based on the supplier model.

• For 503B outsourcing facilities, emphasis is placed on manufacturing-grade quality systems, inspection history, and adherence to federal standards governing bulk sterile compounding.

• For 503A compounding pharmacies, evaluation extends beyond compliance into clinical integration (including prescribing workflows, formulation consistency, and the ability to support patient-specific care).

Due diligence for 503Bs should extend beyond basic verification and include documented review of regulatory status, quality systems, and operational controls. 

It is not enough to verify that a facility is registered, due diligence should be documentable, repeatable, and auditable. Organizations should be able to demonstrate that they have evaluated how that facility operates, how products are compounded, and how quality is consistently maintained.

Due diligence for 503As is more focused on whether the pharmacy can reliably support patient care pathways and ongoing treatment programs. 

It should extend beyond verifying compliance to evaluating whether the pharmacy can function as a consistent, transparent, and prescription-aligned clinical partner. Assessment should emphasize prescribing workflows, consistency, and clinical reliability, in addition to regulatory oversight. 

For medical spas and clinical organizations, this distinction is critical.

A pharmacy is not simply a vendor, it is often functioning as an extension of the clinical delivery model.

Some med spas and wellness organizations now publicly disclose pharmacy relationships as part of their compliance and transparency frameworks—reflecting how central these relationships are to care delivery and risk management. And although med spas may rely on visible credibility signals (e.g., accreditation, verification platforms) as an initial filter, these should always be supported by deeper operational and compliance due diligence.

Read Next: 503A vs. 503B Compounding & FDA Regulations Guide

Why This Matters Now: GLP-1s, Peptides, and Regulatory Shift 

Recent regulatory activity affecting GLP-1 medications and a range of peptide bulk drug substances (with many under review) highlights a broader shift in compounding oversight.

Across these categories, the FDA has signaled:

• Tighter boundaries around the use of certain bulk drug substances in compounding

• Increased scrutiny of high-demand therapeutic categories

• And a move toward more clearly defined (but still evolving) compounding regulations

This introduces a key operational reality: Medication sourcing decisions that were once considered stable may now be time-sensitive and subject to regulatory change.

For both pharmacies and med spas, this reinforces the need to evaluate not only:

• Whether a supplier is compliant today, but also

• Whether that supplier can remain compliant as regulatory expectations evolve

We’ve written more on the far-reaching effects of GLP-1 medications on U.S. compounding in this analysis. 

A Practical Approach to Supplier Evaluation

Given the complexity of the compounding landscape, organizations benefit from translating these principles into a structured, standardized evaluation process.

This typically includes:

• Formal onboarding criteria for new suppliers

• Documented review of regulatory and quality indicators

• Ongoing monitoring of supplier status and performance

• Internal processes for tracking sourcing decisions and associated risk

Organizations that rely on informal or ad hoc evaluation processes are more likely to encounter gaps in documentation, traceability, and regulatory defensibility.

Core Medication Sourcing & Safety Protocols

Both medical spas and pharmacies should implement consistent internal protocols to ensure medication integrity and traceability across suppliers.

Product Verification

• Confirm supplier licensure and authorization to compound and distribute

• Verify FDA registration status of outsourcing facilities

• Review certificates of analysis (COAs) and available batch documentation

Storage and Handling

• Maintain appropriate temperature control and cold-chain monitoring where required

• Ensure compliant storage conditions based on product stability requirements

• Track expiration dates, beyond-use dates (BUDs), and lot numbers

Documentation and Traceability

Maintain complete records of:

• Product receipt and chain of custody

• Storage conditions and handling logs

• Patient administration records

• Patient consent or disclosure documentation related to compounded medications (where applicable depending on state law)

• Lot and batch traceability data

Adverse Event Reporting

Where applicable, adverse events should be documented and reported through FDA MedWatch in accordance with regulatory expectations.

Patient Safety and Enforcement Context

Recent enforcement actions involving compounded medications in aesthetic and wellness settings have highlighted risks associated with:

• Improper sterile compounding practices

• Counterfeit or unverified injectable products

• Repackaging of sterile medications under non-compliant conditions

Reported cases have included:

• Counterfeit medications produced outside regulated facilities

• Sterility failures involving compounded therapies

• Improper handling or repackaging of injectable products in non-sterile environments

Factors such as inadequate oversight, poor compounding practices, and lack of adverse event reporting can increase the risks associated with outsourced CSPs. These cases underscore increased regulatory focus on sourcing integrity, sterile compounding standards, and clinical oversight in med spa environments.

For this reason, performing due diligence when selecting 503A and 503B partners to provide compounding services is essential to risk management. 

Reflective Lens: Pharmacy Due Diligence in Reverse

While this framework is typically applied by med spas evaluating pharmacies, it also serves as a useful reflective exercise for pharmacy operators.

The same due diligence principles—regulatory compliance, documentation rigor, sourcing integrity, and traceability—are increasingly being used by downstream clinical partners to evaluate pharmacy reliability.

In practice, this means pharmacies are not only assessing their own suppliers, but are also being assessed through the same operational and compliance lens by the med spas and clinical organizations they serve.

Essentially, this assessment looks at whether that pharmacy can function as a dependable, compliant extension of their clinical model under increasing regulatory scrutiny.

If you are a 503A or 503B entity supplying compounded products, you can—and should—use this framework to assess your own readiness as a partner. This includes how your processes, documentation, communication, and regulatory positioning would withstand external evaluation by a clinical organization.

Moving from Principles to Practice 

To support organizations in operationalizing these concepts, we’ve developed a structured Compounded Medication Due Diligence Audit Tool that standardizes evaluation across both 503A and 503B partners.

This tool is designed to:

• Translate high-level due diligence principles into actionable criteria

• Support consistent supplier onboarding and review

• Provide documentation for internal audits and regulatory readiness

It includes a scored checklist, clear scoring instructions, dedicated sections for evaluating 503A vs 503B partners, and red flag alerts. 

👉 https://mailchi.mp/1dcfefe2ce3b/0a5dxebv0a

Final Perspective: From Product Sourcing to Regulatory Adaptation

The evolving treatment of GLP-1 medications and peptide bulk drug substances highlights a broader shift in compounding oversight: medication sourcing is no longer defined by fixed categories of “allowed” or “not allowed,” but by an active and changing regulatory environment.

For 503A pharmacies, 503B outsourcing facilities, and medical spas, this means that compliance is no longer a static verification exercise tied to licensure alone. It now requires ongoing evaluation of:

• Where a product sits within FDA classification frameworks (including interim lists and advisory review status)

• Whether current sourcing practices remain aligned with evolving regulatory interpretation and enforcement priorities

• How quickly suppliers can adapt to reclassification or removal from permissible compounding categories

GLP-1s and peptides illustrate this shift clearly: they are not isolated compliance issues, but examples of therapeutic categories moving through active regulatory refinement in real time.

As a result, supplier due diligence is evolving from a one-time procurement decision into a continuous assessment of regulatory alignment, operational transparency, and adaptability within a shifting compounding landscape. It is a shared responsibility across clinical, compounding, and operational stakeholders.

As regulatory expectations continue to evolve, organizations that implement structured, transparent, and adaptive due diligence processes will be better positioned to maintain both compliance and continuity of care.

If you’re looking to understand how these regulations apply to your business, we’re always open to a conversation. 

References

American Society of Health-System Pharmacists, ASHP guidelines on outsourcing sterile compounding services; American Society of Health-System Pharmacists Research and Education Foundation. (2021). Outsourcing sterile products preparation: Vendor assessment tool. Retrieved from https://outsourcing.ashp.org/

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. (2026). https://www.fda.gov/media/94155/download 

Compounding Oversight and Compliance Actions. (2022). FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-oversight-and-compliance-actions 

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. (2026). U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list 

ISMP Guidelines for Sterile Compounding and the Safe Use of Sterile Compounding Technology. (2022). https://www.ismp.org/system/files/resources/2022-04/ISMP195-Compouding%20Guidelines%20v1-042722-2.pdf 

July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committ. (2026). U.S. Food and Drug Administration. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 

Rosebush, L., Holmes, L., & Wagner, M. (2022). Practical Guidance ® Due Diligence in Drug Compounding M&A Deals A Practical Guidance ® Practice Note by. https://admin.bakerlaw.com/wp-content/uploads/2023/07/Due-Diligence-in-Drug-Compounding-MA-Deals.pdf  

Disclaimer: This article is intended to provide general information on U.S. compounding. It should not be construed as legal, regulatory, or medical advice. Readers are encouraged to consult an attorney for guidance specific to their circumstances.